- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00334152
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
21 de marzo de 2017 actualizado por: GlaxoSmithKline
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
Descripción general del estudio
Estado
Terminado
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
515
Fase
- Fase 3
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Baden-Wuerttemberg
-
Freiburg, Baden-Wuerttemberg, Alemania, 79110
- GSK Investigational Site
-
-
Hessen
-
Marburg, Hessen, Alemania, 35043
- GSK Investigational Site
-
-
Mecklenburg-Vorpommern
-
Neubrandenburg, Mecklenburg-Vorpommern, Alemania, 17036
- GSK Investigational Site
-
Rostock, Mecklenburg-Vorpommern, Alemania, 18059
- GSK Investigational Site
-
Schwerin, Mecklenburg-Vorpommern, Alemania, 19055
- GSK Investigational Site
-
Wismar, Mecklenburg-Vorpommern, Alemania, 23966
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Ludwigshafen, Rheinland-Pfalz, Alemania, 67063
- GSK Investigational Site
-
-
Saarland
-
Homburg, Saarland, Alemania, 66421
- GSK Investigational Site
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Alemania, 06120
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Alemania, 24105
- GSK Investigational Site
-
-
-
-
-
Aalst, Bélgica, 9300
- GSK Investigational Site
-
Brasschaat, Bélgica, 2930
- GSK Investigational Site
-
Bruxelles, Bélgica, 1200
- GSK Investigational Site
-
Gent, Bélgica, 9000
- GSK Investigational Site
-
-
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- GSK Investigational Site
-
Toronto, Ontario, Canadá, M5G 1X5
- GSK Investigational Site
-
-
Quebec
-
Sainte-Foy, Quebec, Canadá, G1V 4G2
- GSK Investigational Site
-
Sherbrooke, Quebec, Canadá, J1H 5N4
- GSK Investigational Site
-
-
-
-
-
Badalona, España, 08916
- GSK Investigational Site
-
Barcelona, España, 08025
- GSK Investigational Site
-
Barcelona, España, 08035
- GSK Investigational Site
-
Barcelona, España, 08003
- GSK Investigational Site
-
La Coruña, España, 15006
- GSK Investigational Site
-
Mataro, España, 08034
- GSK Investigational Site
-
Pamplona, España, 31008
- GSK Investigational Site
-
Santiago de Compostela, España, 15706
- GSK Investigational Site
-
-
-
-
Alabama
-
Fairhope, Alabama, Estados Unidos, 36532
- GSK Investigational Site
-
Mobile, Alabama, Estados Unidos, 36608
- GSK Investigational Site
-
Montgomery, Alabama, Estados Unidos, 36106
- GSK Investigational Site
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- GSK Investigational Site
-
-
California
-
Arcadia, California, Estados Unidos, 91007
- GSK Investigational Site
-
Glendale, California, Estados Unidos, 91206
- GSK Investigational Site
-
Laguna Hills, California, Estados Unidos, 92653
- GSK Investigational Site
-
Pasadena, California, Estados Unidos, 91105
- GSK Investigational Site
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33067
- GSK Investigational Site
-
Melbourne, Florida, Estados Unidos, 32901
- GSK Investigational Site
-
Miami, Florida, Estados Unidos, 33143
- GSK Investigational Site
-
West Palm Beach, Florida, Estados Unidos, 33409
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- GSK Investigational Site
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21229-5299
- GSK Investigational Site
-
-
Michigan
-
Royal Oak, Michigan, Estados Unidos, 48073
- GSK Investigational Site
-
-
New York
-
Mineola, New York, Estados Unidos, 11501
- GSK Investigational Site
-
New Hyde Park, New York, Estados Unidos, 11040
- GSK Investigational Site
-
New York, New York, Estados Unidos, 10038
- GSK Investigational Site
-
-
North Carolina
-
Winston-Salem, North Carolina, Estados Unidos, 27103
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45208
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- GSK Investigational Site
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- GSK Investigational Site
-
Winchester, Virginia, Estados Unidos, 22601
- GSK Investigational Site
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- GSK Investigational Site
-
-
-
-
-
Moscow, Federación Rusa, 101000
- GSK Investigational Site
-
Moscow, Federación Rusa, 111538
- GSK Investigational Site
-
Moscow, Federación Rusa, 117152
- GSK Investigational Site
-
Perm, Federación Rusa, 614107
- GSK Investigational Site
-
St. Petersburgh, Federación Rusa, 192242
- GSK Investigational Site
-
-
-
-
-
Manila, Filipinas, 1000
- GSK Investigational Site
-
Quezon, City, Filipinas, 1104
- GSK Investigational Site
-
-
-
-
-
Kwun Tong, Hong Kong
- GSK Investigational Site
-
Pokfulam, Hong Kong
- GSK Investigational Site
-
Shatin, New Territories, Hong Kong
- GSK Investigational Site
-
Sheung Shui, New Territories, Hong Kong
- GSK Investigational Site
-
-
-
-
-
Lahore, Pakistán
- GSK Investigational Site
-
-
-
-
-
Brno, República Checa, 625 00
- GSK Investigational Site
-
Jihlava, República Checa, 586 01
- GSK Investigational Site
-
Olomouc, República Checa, 775 20
- GSK Investigational Site
-
Pardubice, República Checa, 532 03
- GSK Investigational Site
-
Praha 2, República Checa, 128 51
- GSK Investigational Site
-
Praha 5, República Checa, 150 08
- GSK Investigational Site
-
-
-
-
-
Bangkok, Tailandia
- GSK Investigational Site
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Femenino
Descripción
Inclusion criteria:
- History of PONV (postoperative nausea and vomiting) and/or motion sickness.
- Have not smoked for the last 6 months.
- Having certain abdominal, breast, thyroid or shoulder surgery.
Exclusion criteria:
- Pregnant or breastfeeding.
- Have certain pre-existing medical conditions or take certain medications.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants who achieved a complete response
Periodo de tiempo: Up to 24 hours
|
Complete response defined as no vomiting or retching and no rescue therapy during the first 24 hours following placement of the last suture/staple.
Vomiting defined as the forceful expulsion of gastrointestinal contents through the mouth or nose.
Retching defined as the labored, spasmodic, rhythmic contraction of the respiratory and abdominal muscles in an attempt to vomit that is not productive of gastrointestinal contents (also known as "dry heaves").
Study participants who receive antiemetic rescue medication(s) during the initial 24 hours was considered treatment failures.
|
Up to 24 hours
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by an 11-point, linear, numerical rating scale referred to as a "0-10 Likert scale"
Periodo de tiempo: Up to 48 hours
|
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements.
Each participant completed a Likert scale at 2, 6, 24 and 48 hours after placement of the last suture/staple.
The Likert scale used a range of 0-10, where 0 = no nausea and 10 = nausea as bad as it could be.
|
Up to 48 hours
|
|
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by a categorical scale (none, mild, moderate or severe), as defined in the protocol
Periodo de tiempo: Up to 48 hours
|
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements.
Each participant completed a categorical scale at 2, 6, 24 and 48 hours after placement of the last suture/staple.
In the categorical scale, each participant asked to rate the severity of nausea as, none: no nausea, mild: queasiness/upset stomach that is manageable and minimally (if at all) affects daily activities, moderate: increased queasiness, sometimes with the feeling of having to vomit (but not vomiting), that has a significant negative effect on daily activities (for example, being unable to work, eat and drink, prepare food, care for children or others), severe: feeling sick and vomiting or feeling like you are going to vomit, and unable to perform most daily activities.
|
Up to 48 hours
|
|
Number of participants with first emetic event
Periodo de tiempo: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with first antiemetic rescue medication
Periodo de tiempo: Up to 48 hours
|
Up to 48 hours
|
|
|
Participant satisfaction with the prophylactic antiemetic regimens, as assessed by participant satisfaction assessments in the participant diary
Periodo de tiempo: Up to 48 hours
|
Up to 48 hours
|
|
|
Participant willingness of participants to use the same treatment regimen for future surgical procedures, as assessed by participant satisfaction assessments in the participant diary
Periodo de tiempo: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with chemistry data outside the reference range
Periodo de tiempo: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with hematology data outside the reference range
Periodo de tiempo: Up to 48 hours
|
Up to 48 hours
|
|
|
Safety and tolerability of the antiemetic regimens, assessed by clinical observation (including time to awakening from anesthesia, defined as ability to respond to a verbal command)
Periodo de tiempo: Up to 24 hours
|
Up to 24 hours
|
|
|
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Periodo de tiempo: Up to Days 6-14 visit
|
An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use.
The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.
Refer to the general AE/SAE module for a list of AEs and SAEs.
|
Up to Days 6-14 visit
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de marzo de 2006
Finalización primaria (Actual)
1 de julio de 2006
Finalización del estudio (Actual)
1 de julio de 2006
Fechas de registro del estudio
Enviado por primera vez
2 de junio de 2006
Primero enviado que cumplió con los criterios de control de calidad
2 de junio de 2006
Publicado por primera vez (Estimar)
6 de junio de 2006
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
23 de marzo de 2017
Última actualización enviada que cumplió con los criterios de control de calidad
21 de marzo de 2017
Última verificación
1 de marzo de 2017
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Complicaciones Postoperatorias
- Signos y Síntomas Digestivos
- Náuseas
- Vómitos
- Náuseas y vómitos postoperatorios
- Efectos fisiológicos de las drogas
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Agentes Autonómicos
- Agentes del sistema nervioso periférico
- Antieméticos
- Agentes Gastrointestinales
- Antagonistas del receptor de neuroquinina-1
- Casopitant
Otros números de identificación del estudio
- NKT102552
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Sí
Descripción del plan IPD
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Datos del estudio/Documentos
-
Especificación del conjunto de datos
Identificador de información: NKT102552Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Conjunto de datos de participantes individuales
Identificador de información: NKT102552Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulario de informe de caso anotado
Identificador de información: NKT102552Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulario de consentimiento informado
Identificador de información: NKT102552Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocolo de estudio
Identificador de información: NKT102552Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Informe de estudio clínico
Identificador de información: NKT102552Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Plan de Análisis Estadístico
Identificador de información: NKT102552Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .